The Transcriptional Repressor ZEB1 Promotes Metastasis and Loss of Cell Polarity in Cancer

  • Simone Spaderna
    1Department of Visceral Surgery, University of Freiburg, Freiburg, Germany;
  • Otto Schmalhofer
    1Department of Visceral Surgery, University of Freiburg, Freiburg, Germany;
  • Mandy Wahlbuhl
    2Department of Pathology and
  • Arno Dimmler
    2Department of Pathology and
  • Katja Bauer
    3Nikolaus-Fiebiger-Center, University of Erlangen, Erlangen, Germany;
  • Aneesa Sultan
    4Max F. Perutz Laboratories, Medical University Vienna, Vienna, Austria;
  • Falk Hlubek
    5Department of Pathology, University of Munchen, Munich, Germany; and
  • Andreas Jung
    5Department of Pathology, University of Munchen, Munich, Germany; and
  • Dennis Strand
    6First Department of Internal Medicine, University of Mainz, Mainz, Germany
  • Andreas Eger
    4Max F. Perutz Laboratories, Medical University Vienna, Vienna, Austria;
  • Thomas Kirchner
    5Department of Pathology, University of Munchen, Munich, Germany; and
  • Jürgen Behrens
    3Nikolaus-Fiebiger-Center, University of Erlangen, Erlangen, Germany;
  • Thomas Brabletz
    1Department of Visceral Surgery, University of Freiburg, Freiburg, Germany;

説明

<jats:title>Abstract</jats:title> <jats:p>Invasion and metastasis are the hallmarks of malignant tumor progression and the main cause of death in cancer. The embryonic program “epithelial-mesenchymal transition” (EMT) is thought to trigger invasion by allowing tumor cell dissemination. Here, we describe that the EMT-inducing transcriptional repressor ZEB1 promotes colorectal cancer cell metastasis and loss of cell polarity. Thereby, ZEB1 suppresses the expression of cell polarity factors, in particular of Lgl2, which we found reduced in colorectal and breast cancers. We further show that retention of Lgl2 expression is critical for the epithelial phenotype and that its loss might be involved in metastasis. Thus, by linking EMT, loss of polarity, and metastasis, ZEB1 is a crucial promoter of malignant tumor progression. [Cancer Res 2008;68(2):537–44]</jats:p>

収録刊行物

  • Cancer Research

    Cancer Research 68 (2), 537-544, 2008-01-15

    American Association for Cancer Research (AACR)

被引用文献 (12)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ